 |
197 Diseases |  |
398 Trials |
|
398 Trials |  |
21826 News |  |
| «12...254255256257258259260261262263264...266267» |
- || Provenge (sipuleucel-T) / Bausch Health
Trial primary completion date: NCI-2014-00318: Sipuleucel-T With Immediate vs. Delayed Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Blockade for Prostate Cancer (clinicaltrials.gov) - Jan 12, 2015
P2, N=54, Recruiting, Sponsor: Lawrence Fong
Trial primary completion date: Dec 2015 --> Jun 2016
- Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap, Yervoy (ipilimumab) / BMS
Trial initiation date, Trial primary completion date, Metastases: CD8+ Antigen-Specific T Cells, Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Melanoma (clinicaltrials.gov) - Jan 12, 2015
P2, N=20, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Dec 2015 --> Jun 2016 Initiation date: Nov 2014 --> Apr 2015 | Trial primary completion date: Nov 2018 --> Apr 2019
- ||| Leukine (sargramostim) / Partner Therap, Yervoy (ipilimumab) / BMS
Trial initiation date: Ipilimumab and GMCSF Immunotherapy for Prostate Cancer (clinicaltrials.gov) - Jan 12, 2015
P2, N=54, Not yet recruiting, Sponsor: Lawrence Fong
Initiation date: Nov 2014 --> Apr 2015 | Trial primary completion date: Nov 2018 --> Apr 2019 Initiation date: Aug 2014 --> Mar 2015
- Yervoy (ipilimumab) / BMS
Enrollment change: Chemoradiation Therapy and Ipilimumab in Treating Patients With Stages IB2-IIB or IIIB-IVA Cervical Cancer (clinicaltrials.gov) - Jan 9, 2015
P1, N=28, Recruiting, Sponsor: National Cancer Institute (NCI)
Initiation date: Aug 2014 --> Mar 2015 N=18 --> 28
- ||| epacadostat (INCB024360) / Incyte
Enrollment closed, Combination therapy, Metastases: A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (clinicaltrials.gov) - Jan 9, 2015
P1/2, N=136, Active, not recruiting, Sponsor: Incyte Corporation
N=18 --> 28 Recruiting --> Active, not recruiting
- | Yervoy (ipilimumab) / BMS
Enrollment closed, Metastases: First-Line Gemcitabine, Cisplatin + Ipilimumab for Metastatic Urothelial Carcinoma (clinicaltrials.gov) - Jan 9, 2015
P2, N=36, Active, not recruiting, Sponsor: Hoosier Cancer Research Network
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- || Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment change, Trial primary completion date: Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma (clinicaltrials.gov) - Jan 8, 2015
P1, N=62, Recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Recruiting --> Active, not recruiting N=85 --> 62 | Trial primary completion date: May 2015 --> Dec 2015
- | cyclophosphamide / Generic mfg.
Trial completion, Enrollment change, Metastases: CTLA-4 Blockade and Low Dose Cyclophosphamide in Patients With Advanced Malignant Melanoma (clinicaltrials.gov) - Jan 8, 2015
P2, N=11, Completed, Sponsor: Mount Sinai School of Medicine
N=85 --> 62 | Trial primary completion date: May 2015 --> Dec 2015 Active, not recruiting --> Completed | N=29 --> 11
- |||| Yervoy (ipilimumab) / Ono Pharma, BMS
Trial primary completion date, Metastases: Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Plus Paclitaxel and Carboplatin Versus Placebo Plus Paclitaxel and Carboplatin (clinicaltrials.gov) - Jan 2, 2015
P3, N=867, Recruiting, Sponsor: Bristol-Myers Squibb
Active, not recruiting --> Completed | N=29 --> 11 Trial primary completion date: Mar 2018 --> Sep 2019
- Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial primary completion date, PD(L)-1 Biomarker: Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant (clinicaltrials.gov) - Jan 2, 2015
P1, N=40, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Mar 2018 --> Sep 2019 Trial primary completion date: Dec 2014 --> Aug 2015
- |||| Yervoy (ipilimumab) / BMS
Enrollment open, Metastases: Safety and Efficacy Study of Ipilimumab 3 mg/kg Versus Ipilimumab 10 mg/kg in Subjects With Metastatic Castration Resistant Prostate Cancer Who Are Chemotherapy Naive (clinicaltrials.gov) - Jan 2, 2015
P2, N=200, Recruiting, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Dec 2014 --> Aug 2015 Not yet recruiting --> Recruiting
- || Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Biomarker, Enrollment closed, Monotherapy, PD(L)-1 Biomarker, IO biomarker: CheckMate 038: PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma (clinicaltrials.gov) - Jan 2, 2015
P1, N=160, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- ||| Imlygic (talimogene laherparepvec) / Amgen
Enrollment change: Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma (clinicaltrials.gov) - Dec 19, 2014
P1/2, N=219, Recruiting, Sponsor: Amgen
Recruiting --> Active, not recruiting N=149 --> 219
- ||||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
New P2 trial, Monotherapy: CheckMate 204: An Investigational Immuno-therapy Study to Evaluate Safety and Effectiveness in Patients With Melanoma That Has Spread to the Brain, Treated With Nivolumab in Combination With Ipilimumab, Followed by Nivolumab by Itself (clinicaltrials.gov) - Dec 19, 2014
P2, N=148, Not yet recruiting, Sponsor: Bristol-Myers Squibb
- CD19CAR-28-zeta T cells / Baylor College of Medicine
Enrollment closed: CRETI-NH: CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, ALL & CLL (clinicaltrials.gov) - Dec 17, 2014
P1, N=54, Active, not recruiting, Sponsor: Baylor College of Medicine
N=149 --> 219 Recruiting --> Active, not recruiting
- Tafinlar (dabrafenib) / Novartis, BeiGene, Yervoy (ipilimumab) / BMS
Enrollment open, Trial initiation date, Trial primary completion date, Metastases: Ipilimumab and Dabrafenib in the 1st Line Tx of Unresectable Stage III/IV Melanoma (clinicaltrials.gov) - Dec 13, 2014
P1/2, N=12, Recruiting, Sponsor: University of Utah
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting | Initiation date: Aug 2014 --> Dec 2014 | Trial primary completion date: Jan 2016 --> Dec 2016
- Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
New P2 trial, PD(L)-1 Biomarker: Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer (clinicaltrials.gov) - Dec 12, 2014
P2, N=37, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
New P1 trial, PD(L)-1 Biomarker, IO biomarker: NRG-BN002: Ipilimumab and/or Nivolumab in Combination With Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma (clinicaltrials.gov) - Dec 10, 2014
P1, N=42, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- | UV1 / Ultimovacs
Enrollment open, Combination therapy, Metastases: Safety of UV1 Vaccination in Combination With Ipilimumab in Patients With Unresectable or Metastatic Malignant Melanoma (clinicaltrials.gov) - Dec 10, 2014
P1/2, N=20, Recruiting, Sponsor: Ultimovacs AS
Not yet recruiting --> Recruiting | Initiation date: Aug 2014 --> Dec 2014 | Trial primary completion date: Jan 2016 --> Dec 2016 Not yet recruiting --> Recruiting
- Yervoy (ipilimumab) / BMS
Trial primary completion date, Monotherapy: Phase II Study of Ipilimumab Monotherapy in Recurrent Platinum-sensitive Ovarian Cancer (clinicaltrials.gov) - Dec 9, 2014
P2, N=40, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Not yet recruiting --> Recruiting Trial primary completion date: Dec 2014 --> Aug 2014
- |||| Yervoy (ipilimumab) / BMS
Trial primary completion date, Metastases: Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer (clinicaltrials.gov) - Dec 9, 2014
P3, N=600, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Dec 2014 --> Aug 2014 Trial primary completion date: Nov 2015 --> Mar 2015
- ||||| Yervoy (ipilimumab) / Ono Pharma, BMS
Trial initiation date, Metastases: Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Versus Placebo in Addition to Paclitaxel and Carboplatin (clinicaltrials.gov) - Dec 9, 2014
P3, N=920, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Nov 2015 --> Mar 2015 Initiation date: Jan 2011 --> Aug 2011
- || Opdivo (nivolumab) / BMS
Monotherapy, PD(L)-1 Biomarker, IO biomarker: CheckMate 039: An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma (clinicaltrials.gov) - Dec 9, 2014
P1, N=315, Recruiting, Sponsor: Bristol-Myers Squibb
Initiation date: Jan 2011 --> Aug 2011 N=180 --> 315
- |||||| Yervoy (ipilimumab) / Ono Pharma, BMS
Enrollment open, Metastases: Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Plus Paclitaxel and Carboplatin Versus Placebo Plus Paclitaxel and Carboplatin (clinicaltrials.gov) - Dec 9, 2014
P3, N=867, Recruiting, Sponsor: Bristol-Myers Squibb
N=180 --> 315 Not yet recruiting --> Recruiting
- |||||| Yervoy (ipilimumab) / Ono Pharma, BMS
Enrollment open: Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone (clinicaltrials.gov) - Dec 9, 2014
P3, N=1125, Recruiting, Sponsor: Bristol-Myers Squibb
Not yet recruiting --> Recruiting Active, not recruiting --> Recruiting
- | Yervoy (ipilimumab) / BMS
Trial completion, Trial initiation date, Trial primary completion date, Metastases: Study to Compare the Effect of Ipilimumab Retreatment With That of Chemotherapy in Advanced Melanoma (clinicaltrials.gov) - Dec 9, 2014
P2, N=23, Completed, Sponsor: Bristol-Myers Squibb
Active, not recruiting --> Recruiting Active, not recruiting --> Completed | Initiation date: Nov 2012 --> Mar 2013 | Trial primary completion date: May 2015 --> Jul 2014
- | Cavatak (gebasaxturev) / Merck (MSD)
New P1 trial, Metastases: Intratumoral CAVATAK (CVA21) and Ipilimumab in Patients With Advanced Melanoma (VLA-013 MITCI) (clinicaltrials.gov) - Dec 7, 2014
P1, N=26, Not yet recruiting, Sponsor: Viralytics
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
New P1/2 trial, Tumor mutational burden, PD(L)-1 Biomarker, IO biomarker: Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas (clinicaltrials.gov) - Dec 5, 2014
P1/2, N=160, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- | Avastin (bevacizumab) / Roche, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment open, PD(L)-1 Biomarker: Nivolumab With or Without Bevacizumab or Ipilimumab Before Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed by Surgery (clinicaltrials.gov) - Dec 5, 2014
P2, N=45, Recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed | Initiation date: Nov 2012 --> Mar 2013 | Trial primary completion date: May 2015 --> Jul 2014 Not yet recruiting --> Recruiting
- | Yervoy (ipilimumab) / Ono Pharma, BMS
Trial completion: Pre-Operative, Single-Dose Ipilimumab and/or Cryoablation in Early Stage/Resectable Breast Cancer (clinicaltrials.gov) - Dec 5, 2014
P=N/A, N=19, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Intron A (interferon ?-2b) / Merck (MSD), Biogen, Yervoy (ipilimumab) / BMS
Trial primary completion date, Combination therapy, Surgery, Metastases: E3611: Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery (clinicaltrials.gov) - Dec 1, 2014
P2, N=88, Recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Trial primary completion date: Dec 2014 --> May 2016
- Biomarker, Enrollment open, PD(L)-1 Biomarker, IO biomarker: Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery (clinicaltrials.gov) - Dec 1, 2014
P1, N=40, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Dec 2014 --> May 2016 Suspended --> Recruiting
- | canerpaturev (TBI-1401) / Takara
Enrollment open, Oncolytic virus, Metastases: A Study of Combination Treatment With HF10 and Ipilimumab in Patients With Unresectable or Metastatic Melanoma (clinicaltrials.gov) - Nov 24, 2014
P2, N=43, Recruiting, Sponsor: Takara Bio Inc.
Suspended --> Recruiting Not yet recruiting --> Recruiting
- |||| Yervoy (ipilimumab) / BMS
Enrollment open, Metastases: Ipi4: A National Phase IV Study With Ipilimumab for Patients With Advanced Malignant Melanoma. (clinicaltrials.gov) - Nov 24, 2014
P4, N=100, Recruiting, Sponsor: Oslo University Hospital
Not yet recruiting --> Recruiting Active, not recruiting --> Recruiting
- Yervoy (ipilimumab) / Ono Pharma, BMS
Trial primary completion date, Metastases: Concurrent Ipilimumab and Stereotactic Ablative Radiation Therapy (SART) for Oligometastatic But Unresectable Melanoma (clinicaltrials.gov) - Nov 14, 2014
P2, N=50, Recruiting, Sponsor: Wolfram Samlowski
Active, not recruiting --> Recruiting Trial primary completion date: Oct 2014 --> Nov 2015
- |||||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment open, Monotherapy: Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214) (clinicaltrials.gov) - Nov 14, 2014
P3, N=1070, Recruiting, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Oct 2014 --> Nov 2015 Not yet recruiting --> Recruiting
- Yervoy (ipilimumab) / BMS
Trial primary completion date: Ipilimumab in Treating Patients With Metastatic or Recurrent Human Papilloma Virus-Related Cervical Cancer (clinicaltrials.gov) - Nov 13, 2014
P2, N=44, Recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Trial primary completion date: Nov 2014 --> Jul 2015
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Yervoy (ipilimumab) / BMS
Trial primary completion date, Metastases: Ipilimumab, Cetuximab, and Intensity-Modulated Radiation Therapy in Treating Patients With Previously Untreated Stage III-IVB Head and Neck Cancer (clinicaltrials.gov) - Nov 4, 2014
P1, N=18, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Nov 2014 --> Jul 2015 Trial primary completion date: Sep 2014 --> Oct 2016
- | Yervoy (ipilimumab) / BMS
Enrollment closed, Trial primary completion date: The Addition of Ipilimumab to Carboplatin and Etoposide Chemotherapy for Extensive Stage Small Cell Lung Cancer (clinicaltrials.gov) - Nov 4, 2014
P2, N=40, Active, not recruiting, Sponsor: University Hospital Southampton NHS Foundation Trust.
Trial primary completion date: Sep 2014 --> Oct 2016 Recruiting --> Active, not recruiting | Trial primary completion date: May 2014 --> May 2015
- |||||||||| Yervoy (ipilimumab) / Ono Pharma, BMS
New P3 trial, Metastases: Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Plus Paclitaxel and Carboplatin Versus Placebo Plus Paclitaxel and Carboplatin (clinicaltrials.gov) - Oct 31, 2014
P3, N=867, Not yet recruiting, Sponsor: Bristol-Myers Squibb
- ||||| Yervoy (ipilimumab) / BMS
New P2 trial, Metastases: Safety and Efficacy Study of Ipilimumab 3 mg/kg Versus Ipilimumab 10 mg/kg in Subjects With Metastatic Castration Resistant Prostate Cancer Who Are Chemotherapy Naive (clinicaltrials.gov) - Oct 31, 2014
P2, N=200, Not yet recruiting, Sponsor: Bristol-Myers Squibb
- ||| Yervoy (ipilimumab) / BMS
Enrollment closed, Metastases: Ipi4: A National Phase IV Study With Ipilimumab for Patients With Advanced Malignant Melanoma. (clinicaltrials.gov) - Oct 31, 2014
P4, N=100, Active, not recruiting, Sponsor: Oslo University Hospital
Recruiting --> Active, not recruiting | Trial primary completion date: May 2014 --> May 2015 Recruiting --> Active, not recruiting
- Xalkori (crizotinib) / Pfizer
Trial primary completion date, Checkpoint inhibition, PD(L)-1 Biomarker, IO biomarker: Combination Checkpoint Inhibitor Plus Erlotinib or Crizotinib for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer (clinicaltrials.gov) - Oct 30, 2014
P1, N=46, Recruiting, Sponsor: University of Utah
Recruiting --> Active, not recruiting Trial primary completion date: Dec 2015 --> Dec 2016
- Biomarker, Trial suspension, PD(L)-1 Biomarker, IO biomarker: Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery (clinicaltrials.gov) - Oct 30, 2014
P1, N=40, Suspended, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Dec 2015 --> Dec 2016 Recruiting --> Suspended
- |||||||||| Yervoy (ipilimumab) / Ono Pharma, BMS
New P3 trial, Metastases: Study Comparing TIL to Standard Ipilimumab in Patients With Metastatic Melanoma (clinicaltrials.gov) - Oct 30, 2014
P3, N=162, Recruiting, Sponsor: The Netherlands Cancer Institute
- || Selectikine (EMD 521873) / EMD Serono
Trial primary completion date, Combination therapy, Metastases: EMR 062235-005: MSB0010445 and Stereotactic Body Radiation Therapy in Advanced Melanoma (clinicaltrials.gov) - Oct 28, 2014
P2, N=86, Recruiting, Sponsor: EMD Serono
Recruiting --> Suspended Trial primary completion date: Jun 2015 --> Jan 2016
- | UV1 / Ultimovacs
New P1/2 trial, Combination therapy, Metastases: Safety of UV1 Vaccination in Combination With Ipilimumab in Patients With Unresectable or Metastatic Malignant Melanoma (clinicaltrials.gov) - Oct 27, 2014
P1/2, N=20, Not yet recruiting, Sponsor: Ultimovacs AS
- | canerpaturev (TBI-1401) / Takara
New P2 trial, Oncolytic virus, Metastases: A Study of Combination Treatment With HF10 and Ipilimumab in Patients With Unresectable or Metastatic Melanoma (clinicaltrials.gov) - Oct 23, 2014
P2, N=43, Not yet recruiting, Sponsor: Takara Bio Inc.
- ||||| Yervoy (ipilimumab) / Ono Pharma, BMS
Enrollment closed: Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone (clinicaltrials.gov) - Oct 22, 2014
P3, N=1125, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Jun 2015 --> Jan 2016 Recruiting --> Active, not recruiting
- ||||| Yervoy (ipilimumab) / Ono Pharma, BMS
Enrollment closed, Metastases: Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Versus Placebo in Addition to Paclitaxel and Carboplatin (clinicaltrials.gov) - Oct 22, 2014
P3, N=920, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting